KARIN EASTHAM - 22 Sep 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
22 Sep 2021
Transactions value $
$0
Form type
4
Filing time
24 Sep 2021, 18:15:09 UTC
Previous filing
04 Aug 2021
Next filing
03 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +10,200 +42% $0 34,300 22 Sep 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +20,400 $0 20,400 22 Sep 2021 Common Stock 20,400 $17.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2 This RSU award vests in full, one year following September 22, 2021.
F3 This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.